Breast cancer has five stages, numbered 0 through 4. Each stage describes how far the cancer has grown and whether it has spread beyond the breast. Stage 0 is the earliest and most treatable form, while stage 4 means the cancer has reached other organs. Understanding where you fall on this scale shapes nearly every treatment decision that follows.
How the Five Stages Break Down
The staging system moves from least to most advanced based on three key factors: the size of the tumor, whether cancer cells have reached nearby lymph nodes, and whether the cancer has spread (metastasized) to distant parts of the body. Doctors refer to these three factors as T (tumor), N (nodes), and M (metastasis). Your final stage number combines all three.
Beyond size and spread, staging also accounts for biological characteristics of the cancer cells themselves. Tumors are tested for estrogen receptors, progesterone receptors, and a protein called HER2. These biomarkers reveal how the cancer grows and responds to treatment, and they can shift the final stage assignment up or down. Two tumors of the same size may end up at different stages if their biology differs.
Stage 0: Non-Invasive
Stage 0 is the earliest possible diagnosis. The most common form is ductal carcinoma in situ (DCIS), where abnormal cells line the inside of a milk duct but haven’t broken through the duct wall into surrounding breast tissue. Because the cells lack the ability to invade, stage 0 is considered non-invasive or pre-invasive.
DCIS rarely causes symptoms. It’s almost always caught on a routine mammogram, where it appears as tiny specks of calcium (calcifications) in the breast tissue. The five-year survival rate for localized breast cancer, which includes stage 0, is effectively 100%. Treatment typically focuses on removing the affected area and preventing the cancer from becoming invasive.
Stage 1: Small and Contained
In stage 1, the cancer is small and limited to the breast tissue, though it may also appear in lymph nodes very close to the breast. At this point the tumor is typically no larger than about 2 centimeters, roughly the size of a peanut. Stage 1 is divided into 1A and 1B based on the exact size of the tumor and whether tiny clusters of cancer cells are found in nearby lymph nodes.
Like stage 0, stage 1 falls under the “localized” category for survival statistics. The outlook is excellent, with a five-year relative survival rate of 100%.
Stage 2: Larger or Locally Spread
Stage 2 means the cancer is either larger than in stage 1, has spread to a small number of nearby lymph nodes, or both. It’s split into 2A and 2B. A stage 2A tumor might be small but present in one to three underarm lymph nodes, or it could be between 2 and 5 centimeters with no lymph node involvement. Stage 2B generally describes a tumor between 2 and 5 centimeters that has also reached nearby lymph nodes, or a tumor larger than 5 centimeters that hasn’t.
Stage 2 is still considered highly treatable. When cancer has spread to regional lymph nodes but not to distant organs, the five-year relative survival rate is 87.5%.
Stage 3: Advanced but Not Metastatic
Stage 3 is sometimes called locally advanced breast cancer. The cancer has spread more extensively to lymph nodes near the breast, the chest wall, or the skin of the breast, but it has not reached distant organs. This stage is further divided into 3A, 3B, and 3C, reflecting increasingly extensive local spread.
Stage 3B, for example, includes cancers that have grown into the chest wall or caused visible changes to the breast skin, such as swelling or ulceration. Stage 3C involves cancer in 10 or more underarm lymph nodes or in lymph nodes above or below the collarbone. Despite being more advanced, stage 3 is still regional, and treatment aims for a complete response.
Stage 4: Metastatic Breast Cancer
Stage 4 means the cancer has spread beyond the breast and nearby lymph nodes to distant parts of the body. The most common sites are the bones, liver, lungs, and brain. The size of the original tumor no longer matters for staging purposes once distant metastasis is confirmed.
The five-year relative survival rate for distant-stage breast cancer is 33.8%. While stage 4 is not considered curable with current treatments, many people live for years with metastatic disease. Treatment focuses on controlling the cancer’s growth, managing symptoms, and maintaining quality of life. The specific biomarker profile of the cancer, including hormone receptor and HER2 status, plays a major role in determining which therapies are most effective.
Why Substages Matter
Within the five main stages, you’ll notice substages like 1A, 2B, or 3C. These finer distinctions exist because two cancers at the “same” stage can behave quite differently. A 4-centimeter tumor with no lymph node involvement is a different clinical picture from a 1-centimeter tumor that has reached several nodes, even though both might fall under stage 2.
Your stage may also be described as “clinical” or “pathological.” Clinical staging is the best estimate before surgery, based on imaging and biopsies. Pathological staging comes after surgery, when the removed tissue and lymph nodes are examined under a microscope. Pathological staging is generally more precise, and it sometimes results in a stage that’s higher or lower than the clinical estimate.
What Your Stage Means in Practice
Staging isn’t just a label. It determines the range of treatment options your care team will recommend, shapes expectations about recovery timelines, and helps you understand prognosis in concrete terms. Earlier stages typically involve less extensive surgery and shorter treatment courses. Later stages often require combinations of surgery, radiation, chemotherapy, and targeted therapies that may continue for months or years.
If you’ve recently been staged, keep in mind that the stage assigned at diagnosis stays with you permanently in your medical record, even if treatment eliminates all detectable cancer. A stage 2 cancer that responds completely to treatment is described as stage 2 in remission, not reclassified as stage 0. This original staging remains useful for tracking long-term outcomes and guiding follow-up care.